Lung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and Others), By Sample Type (Tissue Biopsy and Liquid Biopsy), By Panel Type (Multi-Gene Panel and Single-Gene Panel), By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others), By Region and Competition 2020-2030F

Market Overview

The Global Lung Cancer Genomic Testing Medicine Market will grow from USD 1.90 Billion in 2024 to USD 2.59 Billion by 2030 at a 5.30% CAGR. Lung cancer genomic testing medicine encompasses the analysis of tumor deoxyribonucleic acid to identify specific genetic mutations or alterations, enabling the selection of personalized therapeutic strategies for patients. The market's growth is primarily driven by the rising global incidence of lung cancer, continuous advancements in genomic sequencing technologies such as Next-Generation Sequencing, and an increasing imperative for precision medicine approaches in oncology. Enhanced awareness among healthcare professionals and patients regarding the clinical benefits of molecular profiling further supports this expansion.

A significant challenge impeding market expansion is the substantial cost associated with advanced genomic tests, along with the necessity for specialized expertise and extensive bioinformatics infrastructure to interpret complex data accurately. According to the International Association for the Study of Lung Cancer (IASLC) 2024 Global Survey on Biomarker Testing, 67% of respondents estimated that over half of lung cancer patients in their countries received biomarker testing, a considerable increase from 39% in the 2018 survey.

Key Market Drivers

The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities. According to the World Health Organization in February 2024, "Global cancer burden growing, amidst mounting need for services", lung cancer was the most commonly occurring cancer worldwide, with an estimated 2.5 million new cases reported in 2022. This substantial patient population underscores the critical need for genomic testing to identify actionable mutations, enabling personalized medicine strategies to combat disease progression.

Complementing this, technological advancements in genomic sequencing profoundly accelerate market expansion. Innovations in Next-Generation Sequencing platforms have dramatically improved the speed, accuracy, and comprehensiveness of genetic profiling, transitioning from single-gene testing to multi-gene panels and liquid biopsies. These developments allow for rapid identification of complex genomic alterations crucial for selecting appropriate targeted therapies. According to Illumina in October 2025, "Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025", the company reported $229 million in research and development expenses during the third quarter of 2025, reflecting continuous investment in advancing sequencing capabilities. Such sustained investment drives the development and commercialization of new tools, contributing to increased adoption in clinical practice. The overall market's operational landscape further highlights these advancements. According to Medscape in March 2025, "Delays in Genomic Testing Hinder Lung Cancer Treatment", more than 35,000 genomic tests were being completed each month in England, demonstrating the significant volume of testing undertaken.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.

The direct consequence is a reduced market volume for genomic testing services and products. According to the International Association for the Study of Lung Cancer's (IASLC) 2024 Global Survey on Biomarker Testing, cost was identified as the highest ranked barrier, cited by 27.2% of respondents. This indicates that a considerable portion of the healthcare community perceives test cost as a primary obstacle, hindering the widespread application of these advanced diagnostics. The inability to fully integrate these tests into routine clinical practice due to financial considerations directly slows market expansion by limiting the number of eligible patients who receive testing.

Key Market Trends

Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed. In April 2025, Roche also received FDA Breakthrough Device Designation for its VENTANA TROP2 RxDx Device, an AI-powered companion diagnostic for non-small cell lung cancer, which uses an AI algorithm for quantitative TROP2 scoring to improve diagnostic precision. This integration streamlines diagnostics and treatment planning.

The emergence of genomic testing in early lung cancer screening is a pivotal trend, shifting diagnostics toward proactive detection when treatment is most effective, thereby significantly improving patient outcomes. Despite screening recommendations, the American Lung Association's (ALA) State of Lung Cancer 2024 report noted only 16% of high-risk individuals in the U.S. were screened, highlighting a substantial market opportunity. Guardant Health's Shield Multi-Cancer Detection test, for example, was selected for the National Cancer Institute's Vanguard Study, which began enrolling up to 24,000 individuals in July 2025. This study evaluates multi-cancer detection technologies for lung cancer, fostering broader integration of genomic tests into early detection protocols. This application targets a new patient population, expanding the market.

Segmental Insights

The Polymerase Chain Reaction (PCR) segment is experiencing rapid expansion within the Global Lung Cancer Genomic Testing Medicine Market due to its established advantages in molecular diagnostics. PCR offers a cost-effective and highly sensitive method for detecting specific genetic mutations associated with lung cancer, even when only minute amounts of DNA are available. This technique's ability to provide rapid and accurate results contributes significantly to its increasing adoption for timely treatment decisions. Furthermore, regulatory bodies such as the U.S. Food and Drug Administration (FDA) have approved PCR-based companion diagnostics, like the therascreen® KRAS RGQ PCR kit, which are essential for identifying eligible patients for targeted therapies, thereby reinforcing its pivotal role in personalized lung cancer management.

Regional Insights

North America leads the Global Lung Cancer Genomic Testing Medicine Market, primarily due to its advanced healthcare infrastructure and substantial healthcare expenditure. The region boasts a strong emphasis on research and development, fostering innovation and the swift adoption of advanced diagnostic technologies and personalized medicine approaches. Furthermore, a robust regulatory framework, supported by agencies such as the U.S. Food and Drug Administration and Health Canada, alongside comprehensive reimbursement policies, encourages widespread access to and utilization of genomic testing for lung cancer patients. These combined factors solidify North America's prominent market position.

Recent Developments

• In December 2024, Guardant Health announced a collaboration with Boehringer Ingelheim. The partnership aimed to pursue regulatory approval and commercialization of Guardant360 CDx, a liquid biopsy, as a companion diagnostic for zongertinib. Zongertinib is an investigational covalent tyrosine kinase inhibitor targeting HER2 mutations in non-small cell lung cancer (NSCLC). This collaboration intended to utilize the Guardant360 CDx blood test for comprehensive genomic profiling, identifying NSCLC patients with HER2 mutations who might benefit from treatment with Boehringer Ingelheim's investigational therapy once approved.

• In August 2024, Illumina received Food and Drug Administration (FDA) approval for its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test. This single test interrogates over 500 genes to profile solid tumors, enhancing the likelihood of identifying immuno-oncology or clinically actionable biomarkers. The TSO Comprehensive test also received its first two companion diagnostic (CDx) indications, including one for identifying adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who could benefit from specific targeted therapies.

• In June 2024, Guardant Health introduced an updated version of its Guardant360 TissueNext test. This enhanced tissue genomic profiling test significantly expanded its gene panel, now covering 498 biomarkers. This broader coverage included guideline-recommended genes, aiming to identify additional treatment options for patients with advanced cancer, including lung cancer. The company indicated that the upgraded test was designed to streamline workflow and reduce the time required to deliver results, improving efficiency in treatment selection. This new version also received Medicare coverage for comprehensive genomic profiling of all advanced solid tumors.

• In May 2024, Foundation Medicine commenced the commercial launch of its FoundationOne RNA test in the United States. This tissue-based RNA sequencing test is designed to detect cancer-related fusions across 318 genes, which can be particularly valuable for genomic profiling of various solid tumors, including non-small cell lung cancer (NSCLC). The introduction of this test aimed to provide physicians with a more comprehensive understanding of cancer genomics, enabling more informed decisions for targeted therapeutic selection. The FoundationOne RNA test had previously been available for research and investigational use, and its full commercial availability broadened access to advanced fusion detection.

Key Market Players

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Lung Cancer Genomic Testing Medicine Market, By Technology:

o   Polymerase Chain Reaction

o   Next-Generation Sequencing

o   Fluorescence In-Situ Hybridization

o   Others

• Lung Cancer Genomic Testing Medicine Market, By Sample Type:

o   Tissue Biopsy

o   Liquid Biopsy

• Lung Cancer Genomic Testing Medicine Market, By Panel Type:

o   Multi-Gene Panel

o   Single-Gene Panel

• Lung Cancer Genomic Testing Medicine Market, By End-User:

o   Research Organization

o   Hospitals & Clinics

o   Diagnostic Laboratories

o   Others

• Lung Cancer Genomic Testing Medicine Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Lung Cancer Genomic Testing Medicine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]